Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Zunsemetinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aclaris lays off 46%, resurrects zunsemetinib for cancer
    Aclaris lays off 46%, resurrects zunsemetinib for cancer

    20 Dec 2023

    // James Waldron FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/aclaris-lays-46-staff-resurrects-zunsemetinib-potential-cancer-treatment

    James Waldron FIERCE BIOTECH
    20 Dec 2023
    Share Share
    Aclaris Announces Results from 12-Week Phase 2b Trial of Oral Zunsemetinib
    Aclaris Announces Results from 12-Week Phase 2b Trial of Oral Zunsemetinib

    13 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/13/2778890/37216/en/Aclaris-Therapeutics-Announces-Top-line-Results-from-12-Week-Phase-2b-Trial-of-Oral-Zunsemetinib-ATI-450-for-Moderate-to-Severe-Rheumatoid-Arthritis-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    13 Nov 2023
    Share Share
    Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib
    Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib

    13 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/13/2687010/37216/en/Aclaris-Therapeutics-Completes-Enrollment-in-Phase-2b-Study-of-Oral-Zunsemetinib-ATI-450-for-Moderate-to-Severe-Rheumatoid-Arthritis-ATI-450-RA-202.html

    GLOBENEWSWIRE
    13 Jun 2023
    Share Share